|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Evogen and LGC License High Sensitivity Novel HyBeacons(R) PCR Probe Technology
1/13/2009 10:46:06 AM
KANSAS CITY, Mo. & WHITE MARSH, Md. & BATH, United Kingdom & TEDDINGTON, United Kingdom--(BUSINESS WIRE)--Evogen, Inc., a global molecular diagnostics company, and LGC, an international science-based company and recognised provider of laboratory services and measurement standards, announced today that they have signed a worldwide license agreement of LGC’s HyBeacons® PCR probe chemistry technology to Evogen to augment the recently launched rapid molecular diagnostics and detection platform, including the flagship instrument, the EvoCycler™ HD12. This license gives Evogen exclusive and sub-licensable rights to the HyBeacons technology within its key market areas.
|
|
|
|
|
|
|
|
|
|
|